Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

Cureus Choices and Challenges With Drug Therapy in Postural

PDF) Cognitive Dysfunction in Postural Tachycardia Syndrome.

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Ivabradine in children with postural orthostatic tachycardia

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

PDF) Age-dependent modulation of xenobiotic metabolism in primary

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Ivabradine in children with postural orthostatic tachycardia

Physiological effects of ivabradine in heart failure and beyond

Ivabradine Shows Promise as Tx for Hyperadrenergic POTS - Physician's Weekly

Winning the Lottery: Novel Treatments Return Severely Ill POTS